Growing Inclination of Biopharmaceutical Companies towards Bi-Specific Antibodies

"Increasing numbers of companies are showing curiosity for the development of Bi-Specific Antibodies for the treatment of various diseases" says RNCOS
 
 
Spread the Word
Listed Under

Tag:
* Bi-Specific Antibodies

Industry:
* Health

Location:
* Noida - Uttar Pradesh - India

NOIDA, India - April 4, 2018 - PRLog -- Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. These antibodies are of particular importance for patients who experience recurrence or resistance to drugs.

According to the RNCOS report entitled "Global Bi-Specific Antibodies Market Forecast to 2022", since the last few years, numerous companies have started showing interest in the development bi-specific antibodies. In March 2018, Merus N.V. announced the initiation of development of novel bi-specific antibodies for cancer therapeutics. The Company is developing these bi-specific antibodies in association with the Vall d'Hebron Institute of Oncology by combining Merus' proprietary Biclonics technology platform with VHIO's expertise in clinical, translational and preclinical research.

Furthermore, Zymeworks Inc. announced the initiation of clinical development of its first product, known as ZW49, by utilizing the ZymeLink ADC platform in combination with Zymeworks' Azymetric bispecific platform. The Company is expected to file an IND application to begin trials of ZW49 for the treatment of HER2-expressing cancers.

Similarly, Simcere Pharmaceutical is also planning to develop and commercialize three bi-specific antibodies in China. In order to carry out this research, Simcere will make of use Merus N.V's proprietary Biclonics technology platform. In this deal, Merus will retain the rights on these three bi-specific antibodies outside China.

As per RNCOS latest research reports, many more new biopharmaceutical companies are expected to enter the market in the coming years. Increasing application of bi-specific antibodies in drug development is expected to further increase the revenues of the key players in Global Bi-Specific Antibodies Market.

RNCOS has over a decade of experience in Healthcare Market Reports. We can act as a potential growth partner in all your business endeavours, such as product launching, geographic expansion, sales improvement, distributor/retailer tie-ups etc. Furthermore, RNCOS can help make your business flourish by studying the market dynamics and devising the right strategies.

Feel free to download the latest sample: http://rncos.viewpage.co/Global-Bi-Specific-Antibodies-Market-Forecast-to-2022

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Contact
RNCOS E-Services Pvt. Ltd.
G - 199, Sector - 63, Noida – 201301
***@rncos.com
End
Email:***@rncos.com Email Verified
Tags:Bi-Specific Antibodies
Industry:Health
Location:Noida - Uttar Pradesh - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share